Fabrice Egros - 18 Nov 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Director
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Issuer symbol
SNDX
Transactions as of
18 Nov 2021
Net transactions value
-$127,737
Form type
4
Filing time
19 Nov 2021, 15:06:34 UTC
Previous filing
20 Aug 2021
Next filing
03 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $125,020 +14,000 +88% $8.93 30,000 18 Nov 2021 Direct
transaction SNDX Common Stock Sale $252,452 -14,000 -47% $18.03 16,000 18 Nov 2021 Direct F1, F2
transaction SNDX Common Stock Options Exercise $236 +30 +0.19% $7.88 16,030 18 Nov 2021 Direct
transaction SNDX Common Stock Sale $541 -30 -0.19% $18.03 16,000 18 Nov 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -14,000 -100% $0.000000* 0 18 Nov 2021 Common Stock 0 $8.93 Direct F3
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -30 -100% $0.000000* 0 18 Nov 2021 Common Stock 0 $7.88 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.
F2 The sale prices ranged from $18.03 to $19.03.
F3 This option is fully vested.